Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 11:27:100292.
doi: 10.1016/j.jcte.2021.100292. eCollection 2022 Mar.

Use of estrogen supplementation is associated with higher quality of life scores in women with cystic fibrosis

Malinda Wu  1 , Neha Arora  2 , Viranuj Sueblinvong  3 , William R Hunt  3 , Vin Tangpricha  4
Affiliations

Use of estrogen supplementation is associated with higher quality of life scores in women with cystic fibrosis

Malinda Wu et al. J Clin Transl Endocrinol. .

Abstract

The association of estrogen supplementation use and quality of life in women with cystic fibrosis (CF) is not well characterized. In this cross-sectional study, women with CF completed quality of life questionnaires during a routine CF clinic visit. The use of estrogen supplementation was associated with higher quality of life scores in all domains of the CF questionnaire-revised (CFQ-R) and was significant in the role limitations and respiratory domains. Most participants who were not currently using estrogen supplementation had previously used estrogen supplementation. Most participants had used estrogen to regulate menses, prevent pregnancy and control symptoms around menses. Use of estrogen supplementation was not associated with differences in life-space mobility or screening for sexual dysfunction. This is the largest study to date investigating the association of estrogen supplementation and quality of life in women with CF. Prospective randomized studies are needed to clarify the association of estrogen supplementation and quality of life in women with CF.

Keywords: BMI, Body mass index; CF, Cystic fibrosis; CFQ-R, CF questionnaire-revised; CFTR, CF transmembrane conductance regulator; Contraception; Cystic fibrosis; Ethinyl estradiol; FDA, Food and Drug Administration; FEV1, Forced expiratory volume in 1 second; FSFI-6, Female Sexual Function Index-6; LSA, Life Space Assessment; MCID, Minimal clinical important difference; OCP, Oral contraceptive pill; Quality of Life; SD, Standard deviation; Women’s health; Young adult.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Cystic Fibrosis Foundation Patient Registry 2019 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2020.
    1. About Cystic Fibrosis. (Accessed 06/02/2021, at https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/).
    1. Riordan J.R., Rommens J.M., Kerem B.-S., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–1073. - PubMed
    1. Baiardini I., Steinhilber G., Dim F., Braido F., Solidoro P. Anxiety and depression in cystic fibrosis. Minerva Med. 2015;106:1–8. - PubMed
    1. Ryan J., Burger H.G., Szoeke C., Lehert P., Ancelin M.-L., Henderson V.W., et al. A prospective study of the association between endogenous hormones and depressive symptoms in postmenopausal women. Menopause (New York, NY) 2009;16(3):509–517. - PMC - PubMed

LinkOut - more resources